Sign in to continue:

Wednesday, April 29th, 2026

BONK, INC. SEC Form 8-K Filing Details: Nasdaq Listing, Company Information, and CEO Signature




BONK, Inc. (NASDAQ: BNKK) Files Form 8-K – Key Takeaways for Investors

BONK, Inc. (NASDAQ: BNKK) Files Form 8-K: Key Points for Investors

Overview

On April 28, 2026, BONK, Inc. (trading symbol: BNKK), an emerging growth company listed on the Nasdaq Capital Market, filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC). The report date for this filing is April 22, 2026.

Key Points from the 8-K Filing

  • Form Type: 8-K – Current Report
  • Date of Report (Earliest Event Reported): April 22, 2026
  • Registrant Name: BONK, Inc.
  • Trading Symbols:
    • Common Stock: BNKK
    • Warrants (each exercisable for one share of Common Stock at \$8.50 per share): BNKKW
  • Exchange: The Nasdaq Stock Market LLC (Nasdaq Capital Market)
  • Emerging Growth Company: Yes (BONK, Inc. qualifies as an emerging growth company)

Securities Registered

Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered
Common Stock BNKK NASDAQ (The Nasdaq Capital Market)
Warrants, each exercisable for one share of Common Stock at \$8.50 per share BNKKW NASDAQ (The Nasdaq Capital Market)

Shareholder and Market Sensitive Information

  • No pre-commencement communications or tender offers:
    There are no written communications, soliciting material, or pre-commencement communications reported under Rules 425, 14a-12, 14d-2(b), or 13e-4(c). This means no material merger, acquisition, or significant shareholder action is being disclosed at this time.
  • Emerging Growth Company Status:
    BONK, Inc. is classified as an emerging growth company, which may allow it to take advantage of reduced disclosure and reporting requirements. This status can affect the company’s compliance burdens and may be relevant to investors analyzing costs and regulatory risks.
  • No election for extended transition period:
    BONK, Inc. has not elected to use the extended transition period for complying with new or revised financial accounting standards. This means the company will adopt new accounting standards as they become effective for public companies, potentially impacting how its financials are reported in the future.
  • No amendments reported:
    The filing is not an amendment of a previously filed document, so there are no restatements or corrections disclosed.
  • Departure or Appointment of Directors/Officers:
    The 8-K form references Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), but no details or new events regarding management changes are disclosed in the provided content.

Implications for Shareholders

Based on the information disclosed in this Form 8-K, there are no material events or developments reported that are likely to move the share price in the near term. No mergers, acquisitions, major management changes, or other significant corporate actions have been announced in this filing.

Shareholders should note the company’s continued status as an emerging growth company and the presence of listed warrants, which may affect share dilution if exercised. However, unless there is a material event (such as a merger, acquisition, or leadership change), this routine filing is not likely to be price sensitive.

Conclusion

This Form 8-K is a standard filing with no newsworthy or price-sensitive disclosures at this time. Investors should continue to monitor future filings for any significant events that could impact BONK, Inc.’s share value.


Disclaimer: This article is based solely on the contents of the Form 8-K filing for informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with a financial advisor before making investment decisions.




View BONK, INC. Historical chart here



Aurinia Pharmaceuticals Announces New CEO and Leadership Team Amid Continued Growth in Autoimmune Disease Therapies 1

Aurinia Pharmaceuticals Announces Major Management Changes a...

Ensysce Biosciences Files Certificate of Correction for Series B Preferred Stock with Delaware Secretary of State

Ensysce Biosciences, Inc. Files Certificate of Correction fo...

Monolithic Power Systems, Inc. (MPWR) SEC Filing: Financial Statements, Restatements, and Company Information 2026

Monolithic Power Systems, Inc. Announces Restatement of Fina...

   Ad

Join Our Investing Seminar

Limited seats available — Reserve your spot today